Binding Kinetics in Drug Discovery

被引:32
|
作者
Ferruz, Noelia [1 ,2 ]
De Fabritiis, Gianni [1 ,3 ]
机构
[1] Univ Pompeu Fabra, Computat Biophys Lab GRIB IMIM, Barcelona Biomed Res Pk PRBB, C Dr Aiguader 88, Barcelona 08003, Spain
[2] Acellera, Barcelona Biomed Res Pk PRBB, C Dr Aiguader 88, Barcelona 8808003, Spain
[3] Inst Catalana Recerca & Estudis Avancats, Passeig Lluis Co 23, Barcelona 08010, Spain
关键词
binding kinetics; molecular dynamics; drug discovery; adaptive sampling; GENERAL FORCE-FIELD; MOLECULAR-DYNAMICS; FREE-ENERGY; RESIDENCE TIME; ACCESS CHANNELS; HIV-1; PROTEASE; RECEPTOR; SIMULATIONS; INHIBITOR; DETERMINANTS;
D O I
10.1002/minf.201501018
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Over the last years, researchers have increasingly become interested in measuring and understanding drugs' binding kinetics, namely the time in which drug and its target associate and dissociate. Historically, drug discovery programs focused on the optimization of target affinity as a proxy of in-vivo efficacy. However, often the efficacy of a ligand is not appropriately described by the in-vitro measured drug-receptor affinity, but rather depends on the lifetime of the in-vivo drug-receptor interaction. In this review we review recent works that highlight the importance of binding kinetics, molecular determinants for rational optimization and the recent emergence of computational methods as powerful tools in measuring and understanding binding kinetics.
引用
收藏
页码:216 / 226
页数:11
相关论文
共 50 条
  • [21] The importance of plasma protein binding in drug discovery
    Trainor, George L.
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (01) : 51 - 64
  • [22] A look at ligand binding thermodynamics in drug discovery
    Claveria-Gimeno, Rafael
    Vega, Sonia
    Abian, Olga
    Velazquez-Campoy, Adrian
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2017, 12 (04) : 363 - 377
  • [23] RECEPTOR-BINDING IN THE DRUG DISCOVERY PROCESS
    WILLIAMS, M
    [J]. MEDICINAL RESEARCH REVIEWS, 1991, 11 (02) : 147 - 184
  • [24] Protein-ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modelling
    Bernetti, M.
    Cavalli, A.
    Mollica, L.
    [J]. MEDCHEMCOMM, 2017, 8 (03) : 534 - 550
  • [25] SAR by kinetics for drug discovery in protein misfolding diseases
    Chia, Sean
    Habchi, Johnny
    Michaels, Thomas C. T.
    Cohen, Samuel I. A.
    Linse, Sara
    Dobson, Christopher M.
    Knowles, Tuomas P. J.
    Vendruscolo, Michele
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (41) : 10245 - 10250
  • [26] Tuning drug binding Understanding anticancer drug binding to its target could improve drug discovery and efficacy
    Slade, Dea
    Eustermann, Sebastian
    [J]. SCIENCE, 2020, 368 (6486) : 30 - 31
  • [27] GPCR drug discovery through the exploitation of allosteric drug binding sites
    Rees, S
    Morrow, D
    Kenakin, T
    [J]. RECEPTORS & CHANNELS, 2002, 8 (5-6): : 261 - 268
  • [28] In vivo analysis of drug-receptor binding characteristics in drug discovery
    Yamada, S
    Maruyama, S
    Oki, T
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 : 52P - 52P
  • [29] High throughput screening of drug-protein binding in drug discovery
    Wan, Hong
    Bergstrom, Fredrik
    [J]. JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2007, 30 (5-8) : 681 - 700
  • [30] Molecular simulation of drug-binding kinetics
    Wong, Chung F.
    [J]. MOLECULAR SIMULATION, 2014, 40 (10-11) : 889 - 903